AI news ·
Novo Nordisk and Eli Lilly own nearly all GLP-1 citations in AI search tools, 5W index finds
Novo Nordisk and Eli Lilly account for nearly all GLP-1 drug citations across ChatGPT, Claude, Perplexity, and Google AI Overviews. Their dominance stems from FDA approvals and clinical trial data that AI models treat as authoritative sources.
Two Pharma Giants Control Nearly All GLP-1 Citations in AI Search Tools
Novo Nordisk and Eli Lilly now account for nearly 100% of GLP-1 drug citations across ChatGPT, Claude, Perplexity and Google AI Overviews, according to a new index tracking brand visibility in AI-generated answers about weight loss and metabolic health.
The finding comes from The Weight Loss & Metabolic Health AI Visibility Index 2026, released by 5W. The research analyzed more than 60 consumer prompts across ChatGPT and three other major AI platforms in the first quarter of 2026.
Five GLP-1 brands - Wegovy, Zepbound, Ozempic, Mounjaro and Saxenda - capture 57% of all citations in the $150 billion weight loss category. Wegovy leads at 19%, followed by Zepbound at 16% and Ozempic at 13%.
Why Two Companies Dominate
Novo Nordisk and Eli Lilly hold this position because they are the only sources of FDA-approved chronic weight management drugs and the only sources of the peer-reviewed clinical trial data that AI models cite as evidence.
The companies control what 5W calls a "citation moat" - built through published clinical trials, regulatory approvals treated as content events, and a publication cadence that outpaces the news cycle. AI systems cite these trials repeatedly when answering user questions about weight loss options.
Zepbound's recent rise illustrates the dynamic. When the SURMOUNT-5 trial showed tirzepatide outperformed Wegovy, that single data point now appears in nearly every AI-generated comparison between the two drugs. The citation visibility drove prescription volume.
Legacy Brands Fade
Behavioral weight loss programs and supplements are losing ground in real time. Legacy brands like Jenny Craig, Nutrisystem and Optavia are increasingly framed in AI answers as "before GLP-1s, people tried..." OTC supplements have lost nearly all generic citation share to GLP-1s, with AI models flagging supplement claims with evidence caveats.
Two behavioral programs took different paths. Noom launched a GLP-1 medication access service in 2022 and is now cited as the category's hybrid default. WeightWatchers filed Chapter 11 in 2025, emerged with a GLP-1-focused strategy, and maintained citation share through 60 years of accumulated brand equity.
MyFitnessPal, owned by Francisco Partners, is cited in 60-70% of "best diet app" AI answers. Its 15-year head start building a food database and 200 million-plus user base created an informational moat that newer apps cannot displace.
What This Means for Communicators
The index identifies clinical trial publication as the highest-leverage citation event in weight loss marketing. Brands without peer-reviewed data or regulatory milestones face structural disadvantages in AI-driven search results.
For PR and communications professionals, the finding underscores a shift: AI visibility now depends on building authority across the platforms where decisions happen - ChatGPT, Claude, Perplexity and Google AI Overviews - not just traditional media.
Brands competing in this space need a content strategy aligned with AI citation patterns. That means clinical validation, regulatory events, and editorial coverage at a pace faster than the news cycle.
The full index, including methodology and a 10-point weight loss marketer playbook, is available as a free PDF on 5W's website.